DASATINIB S.K. 50 MG
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DASATINIB
Available from:
K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL
ATC code:
L01XE06
Pharmaceutical form:
FILM COATED TABLETS
Composition:
DASATINIB 50 MG
Administration route:
PER OS
Prescription type:
Required
Manufactured by:
REMEDICA LTD., CYPRUS
Therapeutic area:
DASATINIB
Therapeutic indications:
Dasatinib is indicated for the treatment of adult patients with:• newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;• chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;• Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
Authorization date:
2023-09-20
